Background: Diagnosis of canine adverse food reactions (AFRs) is based on vague criteria, such as ‘>50% improvement’ during elimination diet trial (EDT) followed by ‘deterioration’ during provocation test (PT).Objective: The objective of the study was to use predefined criteria to evaluate response during EDT [i.e., Owner Global Assessment of Treatment Efficacy (OGATE) = good‐to‐excellent] and relapse during PT [i.e., Owner Global Assessment of Challenge Deterioration (OGACD) = moderate‐to‐severe and/or >100% increase of lesional (Canine Atopic Dermatitis Extent and Severity Index, 4th iteration, CADESI‐04) and/or of pruritus (pruritus Visual Analog Scale, PVAS) scores].Animals: Twenty‐nine dogs with atopic dermatitis.Materials and Methods: An extensively hydrolysed diet was fed to all dogs followed, in seven of 11 nonresponders, by a second home‐made novel‐protein EDT. Dogs responding to either EDT were challenged with their previous diet.Results: Thirteen (44.8%) dogs were diagnosed with AFRs: at the end of EDT, their OGATE was good (9 of 13; 69.2%) or excellent (four of 13; 30.8%), and both CADESI‐04 (46.7%) and PVAS (71.1%) had decreased significantly; at the end of PT, OGACD was moderate or severe in 12 of 13 (92.3%) dogs, and both CADESI‐04 (127.9%) and PVAS (181.8%) had increased significantly. Of the 16 dogs without AFRs, 6 (37.5%) responded to the commercial (n = 5) or home‐made (n = 1) diet [OGATE = good (three of six) or excellent (three of six)], with significant concurrent reduction of CADESI‐04 and nonsignificant reduction of PVAS, yet they did not relapse during PT.Conclusions and Clinical Relevance: The proposed (predefined) criteria for the evaluation of response during EDT and deterioration during PT seem reliable and are easily applicable in clinical practice and research.
There is a shortage of studies reporting the efficacy of antimicrobial treatment of dogs with atopic dermatitis (AD) and skin infections (SIs). The aim of this study was to evaluate the change in the severity of skin lesions and pruritus, and the overall efficacy of antimicrobial treatment, in dogs with AD and bacterial overgrowth/infection and/or Malassezia dermatitis. A total of 20 dogs with AD and SIs were prospectively enrolled (group A) and they were examined before and after the administration of systemic antimicrobials that resulted in the resolution of SIs. In addition, 19 dogs fulfilling the same inclusion criteria and treated with systemic, with or without topical antimicrobials, were included retrospectively (group B). Since there were no major differences between the groups, their results were combined. The severity of skin lesions decreased significantly, by 30% based on Canine Atopic Dermatitis Extent and Severity Index-4 (CADESI-4), by 28.1% based on the erythema domain of CADESI-4 and based on owner’s global assessment of the severity of skin lesions. Pruritus decreased significantly, by 34.7% based on the Pruritus Visual Analogue Scale (PVAS). The efficacy of antimicrobial treatment was assessed as good to excellent by the investigator and the owner in 55% and 60% of the dogs, respectively. Despite the significant improvement, there was high variability in the response to treatment among dogs. Further studies are needed to find factors that determine the response to antimicrobial treatment in dogs with AD and SIs.
Background: Identification of offending foods in dogs with adverse food reactions is usually based on “deterioration” during open food challenges. Objectives: To examine the placebo effect during double‐blinded, placebo‐controlled food challenges using a predefined set of criteria for relapse. Animals: Twelve dogs with atopic dermatitis and adverse food reactions. Materials and Methods: Dogs were serially challenged with 40 g/day of eight food items (beef, chicken, codfish, corn flour, cow's milk, hen's egg, lamb, wheat), for 1 week, each mixed with their elimination diet and water. An additional two challenges were placebo (elimination diet mixed with water). Owners and investigators were blinded to the challenges and the order of the 10 challenges was randomised for each dog. Relapse was defined as moderate‐to‐severe owner global assessment of challenge deterioration and/or > 100% increase of Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI‐04) score (with the score at the end being > 9) and/or > 100% increase of pruritus using a Visual Analog Scale (with the score at the end being > 1.9/10). Results: Most (91.7%) dogs were positive to one to six challenges with food items, yet half of them also were falsely positive in one placebo challenge. Two dogs had only one placebo challenge. The number of positive challenges to foods did not differ between dogs with positive and negative placebo challenges. Conclusions and Clinical Relevance: The placebo effect during double‐blinded food challenges creates doubts about the accuracy of the results of challenges with food items in this and in previous studies where open food challenges were used.
The interpretation of intradermal test results may improve if wheal erythema is measured objectively using colorimetry. Our aim was to find the necessary number of erythema colorimetric measurements, taken before and after intradermal injections of histamine 0.01% (H1), histamine 0.001% (H2), histamine 0.0001% (H3) and a negative control (NC). We also aimed to assess whether erythema should be measured at the wheal center or border, and to investigate whether erythema appears beyond histamine wheals (flare), as observed in humans. Duplicate injections of the four solutions were administered on the lateral thorax of seven healthy dogs and erythema was measured by removing and repositioning the colorimeter probe. Colorimetry can differentiate the change in erythema (ΔE) at the center (ΔEc), but not at the border, of the H1 wheals from the ΔE of NC and H3 wheals. Reliable ways to calculate ΔEc were to use the first positive a* axis value of the colorimeter before and after the injection or to obtain the first seven positive a* axis values, excluding the highest and lowest, and calculated the mean of the remaining five. Unlike in humans, intradermal injection of histamine, even at a concentration of 0.01%, did not induce a flare reaction in healthy dogs.